Showing results (1-10 of 258) with videos related to

Sort By:
Pageof 26
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 20, 2010
[Molecular targeted therapy in lung cancer]Koichi Azuma, Kazuhiko Nakagawa
Frontiers in Pharmacology|November 12, 2016
Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer TreatmentTetsuro Sasada, Koichi Azuma, Junya Ohtake, et al.
Thoracic Cancer|September 8, 2022
A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancerDaiki Murata, Koichi Azuma, Saeko Tokisawa, et al.
Cancer Immunology, Immunotherapy : CII|July 5, 2025
Impact of stratifin/14-3-3σ on survival and interstitial lung disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitorsDaiki Murata, Koichi Azuma, Kenta Murotani, et al.
Internal Medicine (Tokyo, Japan)|July 24, 2002
Acute viral encephalitis: the recent progressHiroshi Shoji, Koichi Azuma, Yasuko Nishimura, et al.
Breast Cancer Research and Treatment|June 26, 2004
Identification of HER2/ neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patientsKoichi Azuma, Shigeki Shichijo, Hiroki Shomura, et al.
Investigational New Drugs|August 13, 2020
Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapyHidenobu Ishii, Koichi Azuma, Akihiko Kawahara, et al.
Oncology Letters|November 4, 2014
Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinibHidenobu Ishii, Koichi Azuma, Kazuhiko Yamada, et al.
Annals of Surgical Oncology|November 21, 2007
Prognostic significance of the immediate early response gene X-1 (IEX-1) expression in pancreatic cancerTetsuro Sasada, Koichi Azuma, Tatsuya Hirai, et al.
Investigational New Drugs|January 23, 2021
Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapyNorikazu Matsuo, Koichi Azuma, Takashi Kojima, et al.
Pageof 26